Javascript must be enabled to continue!
An investigation on availability and efficacy of anti-anemic drugs for pigs in the Ukrainian pharmaceuticals
View through CrossRef
Antianemic drugs are used to prevent anemia, majorly iron deficiency anemia. Drugs with such pharmacological action are especially relevant for piglets, as animals of this species at this age are particularly sensitive to iron deficiency. The present investigation aimed at studying the pharmaceutical market of antianemic drugs registered in Ukraine during 2017-2022. It should be noted that if the drug is registered, it has been checked for safety according to the food industry standards of Ukraine. In 2017, the national market of veterinary iron-containing drugs was represented by 13 drugs from the group QB03A “Antianemic drugs. Drugs of iron”, according to the АТС-vet classification. The range of these drugs by 38 % was provided by pharmaceutical products of Ukrainian manufacturers: "O.L.KAR-AgroZooVet-Service", "Pharmaton", "Brovapharma", "Experimental production of the Institute of Epizootology", "Biopharm", and "Vetsintez". Imported products (62 %) were represented by Pharmacosmos, Merial, Koofavet , "Vugen B&G" , "Biovet Pulawy", "Interchem Verken De Adelaar", and "Bioveta". In general, the modern pharmaceutical market of veterinary drugs in Ukraine during 2017–2022 was sufficiently provided with antianemic drugs for pigs and mostly imported drugs. The percentage of antianemic drugs of Ukrainian production prevailed in 2020, however the imported drugs of this pharmacological group's was higher in 2022. It can be concluded that the drugs of non-Ukrainian production predominated among antianemic drugs in Ukraine during 2017-2022. Based on the obtained results, we can state that in Ukraine there is a need for the development and/or production of domestic anti-anemic drugs. They must be effective and ensure a reduction in the dependence of the national pharmaceutical market of drugs of this group on foreign manufacturers.
Title: An investigation on availability and efficacy of anti-anemic drugs for pigs in the Ukrainian pharmaceuticals
Description:
Antianemic drugs are used to prevent anemia, majorly iron deficiency anemia.
Drugs with such pharmacological action are especially relevant for piglets, as animals of this species at this age are particularly sensitive to iron deficiency.
The present investigation aimed at studying the pharmaceutical market of antianemic drugs registered in Ukraine during 2017-2022.
It should be noted that if the drug is registered, it has been checked for safety according to the food industry standards of Ukraine.
In 2017, the national market of veterinary iron-containing drugs was represented by 13 drugs from the group QB03A “Antianemic drugs.
Drugs of iron”, according to the АТС-vet classification.
The range of these drugs by 38 % was provided by pharmaceutical products of Ukrainian manufacturers: "O.
L.
KAR-AgroZooVet-Service", "Pharmaton", "Brovapharma", "Experimental production of the Institute of Epizootology", "Biopharm", and "Vetsintez".
Imported products (62 %) were represented by Pharmacosmos, Merial, Koofavet , "Vugen B&G" , "Biovet Pulawy", "Interchem Verken De Adelaar", and "Bioveta".
In general, the modern pharmaceutical market of veterinary drugs in Ukraine during 2017–2022 was sufficiently provided with antianemic drugs for pigs and mostly imported drugs.
The percentage of antianemic drugs of Ukrainian production prevailed in 2020, however the imported drugs of this pharmacological group's was higher in 2022.
It can be concluded that the drugs of non-Ukrainian production predominated among antianemic drugs in Ukraine during 2017-2022.
Based on the obtained results, we can state that in Ukraine there is a need for the development and/or production of domestic anti-anemic drugs.
They must be effective and ensure a reduction in the dependence of the national pharmaceutical market of drugs of this group on foreign manufacturers.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Prevalence and Risk Factors of Anemia among Patients Hospitalized with Community-Acquired Pneumonia
Prevalence and Risk Factors of Anemia among Patients Hospitalized with Community-Acquired Pneumonia
Anemia is a dangerous association in patients with community-acquired pneumonia (CAP). However, rigorous studies that identify the exact prevalence and risk factors of anemia in in...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Erythropoietin Is Equally Effective as Blood Transfusion at Reducing Infarct Size in Anemic Rats.
Erythropoietin Is Equally Effective as Blood Transfusion at Reducing Infarct Size in Anemic Rats.
Abstract
Abstract 639
Background:
In acute myocardial infarction (MI), anemia may exacerbate ischemia, increasing...
Pu'aka Tonga
Pu'aka Tonga
I have only ever owned one pig. It didn’t have a name, due as it was for the table. Just pu‘aka. But I liked feeding it; nothing from the household was wasted. I planned not to bec...
Feline Erythrocytic Osmotic Fragility in Normal and Anemic Cats—A Preliminary Study
Feline Erythrocytic Osmotic Fragility in Normal and Anemic Cats—A Preliminary Study
Erythrocyte osmotic fragility is an excellent parameter for evaluating the red blood cell (RBC) membrane, which may be abnormal in several pathological conditions. The flow cytomet...

